0000899243-15-007464.txt : 20151103
0000899243-15-007464.hdr.sgml : 20151103
20151103161529
ACCESSION NUMBER: 0000899243-15-007464
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151102
FILED AS OF DATE: 20151103
DATE AS OF CHANGE: 20151103
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 28TH STREET
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 2525 28TH STREET
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MAST ERLE T
CENTRAL INDEX KEY: 0001051411
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 151193874
MAIL ADDRESS:
STREET 1: C/O SPIROS DEVELOPMENT CORP II INC
STREET 2: 7475 LUSK BLVD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-11-02
0
0001466301
Clovis Oncology, Inc.
CLVS
0001051411
MAST ERLE T
C/O CLOVIS ONCOLOGY, INC.
2525 28TH STREET, SUITE 100
BOULDER
CO
80301
0
1
0
0
Executive VP and CFO
Common Stock
2015-11-02
4
S
0
89
98.82
D
138494
D
Common Stock
2015-11-02
4
S
0
111
100.8027
D
138383
D
Common Stock
2015-11-02
4
S
0
100
102.67
D
138283
D
Common Stock
2015-11-02
4
S
0
500
104.284
D
137783
D
Common Stock
2015-11-02
4
S
0
400
105.095
D
137383
D
Common Stock
2015-11-02
4
S
0
1000
106.3302
D
136383
D
Common Stock
2015-11-02
4
S
0
700
107.2886
D
135683
D
Common Stock
2015-11-02
4
S
0
100
108.16
D
135583
D
This transaction was executed in multiple trades at prices ranging from $100.00 to $100.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $103.75 to $104.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $104.83 to $105.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $105.86 to $106.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $106.96 to $107.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2014.
/s/ Erle T. Mast
2015-11-03